Is ATNM or MTVA more profitable?

Actinium Pharmaceuticals' return on equity of -100.85% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Actinium Pharmaceuticals N/A -100.85% -47.89% MetaVia N/A -209.67% -107.91%

Which has better valuation and earnings, MTVA or KYNB?

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Kyntra Bio $6.44M 5.34 $183.45M $45.30 0.19

Is MTVA or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Kyntra Bio 2,199.13% N/A -47.27%

Which has stronger earnings and valuation, MTVA or RADX?

MetaVia has higher earnings, but lower revenue than Radiopharm Theranostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Radiopharm Theranostics $1.88M 16.54 -$24.83M N/A N/A

Is MTVA or RADX more profitable?

Radiopharm Theranostics' return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Radiopharm Theranostics N/A N/A N/A

Do analysts recommend MTVA or BCTX?

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 986.96%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, MTVA or BCTX?

MetaVia is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is MTVA or BCTX more profitable?

Briacell Therap's return on equity of -153.53% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Briacell Therap N/A -153.53% -129.26%

Which has higher valuation & earnings, MTVA or QNCX?

MetaVia is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Quince Therapeutics N/A N/A -$83.98M -$156.71 N/A

Is MTVA or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Quince Therapeutics N/A N/A -133.84%

MetaVia (MTVA) Competitors

$1.84 +0.02 (+1.10%)

As of 09/3/2026 04:00 PM Eastern

Compare

MTVA vs. ATNM, KYNB, RADX, BCTX, and QNCX

Should you buy MetaVia stock or one of its competitors? MetaVia's main competitors and comparable companies include Actinium Pharmaceuticals (ATNM), Kyntra Bio (KYNB), Radiopharm Theranostics (RADX), Briacell Therap (BCTX), and Quince Therapeutics (QNCX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MetaVia compare to Actinium Pharmaceuticals?

Actinium Pharmaceuticals (NYSE:ATNM) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MetaVia has lower revenue, but higher earnings than Actinium Pharmaceuticals. MetaVia is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actinium Pharmaceuticals	$35.09M	0.94	-$48.82M	$0.36	2.92
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

In the previous week, Actinium Pharmaceuticals' average media sentiment score of 0.00 equaled MetaVia'saverage media sentiment score.

Company	Overall Sentiment
Actinium Pharmaceuticals	Neutral
MetaVia	Neutral

Actinium Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Actinium Pharmaceuticals' return on equity of -100.85% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%
MetaVia	N/A	-209.67%	-107.91%

Actinium Pharmaceuticals presently has a consensus price target of $5.00, suggesting a potential upside of 376.19%. MetaVia has a consensus price target of $20.00, suggesting a potential upside of 986.96%. Given MetaVia's higher possible upside, analysts plainly believe MetaVia is more favorable than Actinium Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Actinium Pharmaceuticals beats MetaVia on 6 of the 10 factors compared between the two stocks.

How does MetaVia compare to Kyntra Bio?

MetaVia (NASDAQ:MTVA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

MetaVia has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

MetaVia presently has a consensus price target of $20.00, suggesting a potential upside of 986.96%. Kyntra Bio has a consensus price target of $36.00, suggesting a potential upside of 324.03%. Given MetaVia's higher probable upside, analysts plainly believe MetaVia is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

1.4% of MetaVia shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Kyntra Bio had 5 more articles in the media than MetaVia. MarketBeat recorded 5 mentions for Kyntra Bio and 0 mentions for MetaVia. MetaVia's average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
MetaVia	Neutral
Kyntra Bio	Neutral

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Kyntra Bio	$6.44M	5.34	$183.45M	$45.30	0.19

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Kyntra Bio	2,199.13%	N/A	-47.27%

Summary

Kyntra Bio beats MetaVia on 13 of the 14 factors compared between the two stocks.

How does MetaVia compare to Radiopharm Theranostics?

MetaVia (NASDAQ:MTVA) and Radiopharm Theranostics (NASDAQ:RADX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Radiopharm Theranostics had 1 more articles in the media than MetaVia. MarketBeat recorded 1 mentions for Radiopharm Theranostics and 0 mentions for MetaVia. MetaVia's average media sentiment score of 0.00 equaled Radiopharm Theranostics'average media sentiment score.

Company	Overall Sentiment
MetaVia	Neutral
Radiopharm Theranostics	Neutral

MetaVia has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Radiopharm Theranostics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Radiopharm Theranostics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Radiopharm Theranostics	N/A	N/A	N/A

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 986.96%. Radiopharm Theranostics has a consensus price target of $11.00, indicating a potential upside of 411.63%. Given MetaVia's higher possible upside, equities research analysts clearly believe MetaVia is more favorable than Radiopharm Theranostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Radiopharm Theranostics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

1.4% of MetaVia shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MetaVia has higher earnings, but lower revenue than Radiopharm Theranostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Radiopharm Theranostics	$1.88M	16.54	-$24.83M	N/A	N/A

Summary

Radiopharm Theranostics beats MetaVia on 7 of the 11 factors compared between the two stocks.

How does MetaVia compare to Briacell Therap?

MetaVia (NASDAQ:MTVA) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Briacell Therap's return on equity of -153.53% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Briacell Therap	N/A	-153.53%	-129.26%

MetaVia has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

1.4% of MetaVia shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 0.6% of MetaVia shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, MetaVia's average media sentiment score of 0.00 equaled Briacell Therap'saverage media sentiment score.

Company	Overall Sentiment
MetaVia	Neutral
Briacell Therap	Neutral

MetaVia is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

MetaVia currently has a consensus price target of $20.00, indicating a potential upside of 986.96%. Given MetaVia's stronger consensus rating and higher probable upside, equities analysts plainly believe MetaVia is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MetaVia beats Briacell Therap on 6 of the 11 factors compared between the two stocks.

How does MetaVia compare to Quince Therapeutics?

MetaVia (NASDAQ:MTVA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Quince Therapeutics had 5 more articles in the media than MetaVia. MarketBeat recorded 5 mentions for Quince Therapeutics and 0 mentions for MetaVia. Quince Therapeutics' average media sentiment score of 0.79 beat MetaVia's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MetaVia	Neutral
Quince Therapeutics	Positive

MetaVia is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$156.71	N/A

Quince Therapeutics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Quince Therapeutics	N/A	N/A	-133.84%

MetaVia presently has a consensus price target of $20.00, suggesting a potential upside of 986.96%. Quince Therapeutics has a consensus price target of $260.00, suggesting a potential upside of 751.06%. Given MetaVia's higher possible upside, equities analysts plainly believe MetaVia is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.42

MetaVia has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.31, meaning that its share price is 31% more volatile than the broader market.

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 5.6% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Quince Therapeutics beats MetaVia on 10 of the 14 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.40M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.57	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.39	16.29	12.89	6.14
Net Income	-$12.97M	-$22.72M	$3.47B	$349.01M
7 Day Performance	8.24%	0.34%	0.60%	-0.27%
1 Month Performance	26.03%	8.52%	5.73%	0.68%
1 Year Performance	-75.65%	52.66%	25.35%	14.84%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	1.5079 of 5 stars	$1.84 +1.1%	$20.00 +987.0%	-75.0%	$9.40M	N/A	N/A	8
ATNM Actinium Pharmaceuticals	1.8267 of 5 stars	$1.03 +1.7%	$5.00 +386.9%	-38.6%	$32.38M	$35.09M	N/A	30
KYNB Kyntra Bio	2.3872 of 5 stars	$7.98 -1.5%	$32.50 +307.3%	N/A	$32.32M	$6.44M	0.18	570	Analyst Forecast
RADX Radiopharm Theranostics	2.3415 of 5 stars	$2.24 -3.7%	$11.00 +392.2%	-60.9%	$32.31M	$3.63M	N/A	N/A	Gap Down
BCTX Briacell Therap	0.5902 of 5 stars	$3.71 -7.9%	N/A	-57.2%	$32.08M	N/A	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors

MTVA vs. ATNM, KYNB, RADX, BCTX, and QNCX

How does MetaVia compare to Actinium Pharmaceuticals?

Summary

How does MetaVia compare to Kyntra Bio?

Summary

How does MetaVia compare to Radiopharm Theranostics?

Summary

How does MetaVia compare to Briacell Therap?

Summary

How does MetaVia compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetaVia (MTVA) Competitors

MTVA vs. ATNM, KYNB, RADX, BCTX, and QNCX

How does MetaVia compare to Actinium Pharmaceuticals?

Do institutionals and insiders hold more shares of ATNM or MTVA?

Which has better earnings & valuation, ATNM or MTVA?

Does the media refer more to ATNM or MTVA?

Which has more volatility & risk, ATNM or MTVA?

Is ATNM or MTVA more profitable?

Do analysts rate ATNM or MTVA?

Summary

How does MetaVia compare to Kyntra Bio?

Which has more risk and volatility, MTVA or KYNB?

Do analysts prefer MTVA or KYNB?

Do institutionals and insiders hold more shares of MTVA or KYNB?

Does the media prefer MTVA or KYNB?

Which has better valuation and earnings, MTVA or KYNB?

Is MTVA or KYNB more profitable?

Summary

How does MetaVia compare to Radiopharm Theranostics?

Does the media prefer MTVA or RADX?

Which has more volatility & risk, MTVA or RADX?

Is MTVA or RADX more profitable?

Do analysts recommend MTVA or RADX?

Do institutionals & insiders believe in MTVA or RADX?

Which has stronger earnings and valuation, MTVA or RADX?

Summary

How does MetaVia compare to Briacell Therap?

Is MTVA or BCTX more profitable?

Which has more risk and volatility, MTVA or BCTX?

Do institutionals & insiders believe in MTVA or BCTX?

Does the media prefer MTVA or BCTX?

Which has stronger earnings and valuation, MTVA or BCTX?

Do analysts recommend MTVA or BCTX?

Summary

How does MetaVia compare to Quince Therapeutics?

Does the media refer more to MTVA or QNCX?

Which has higher valuation & earnings, MTVA or QNCX?

Is MTVA or QNCX more profitable?

Do analysts rate MTVA or QNCX?

Which has more risk and volatility, MTVA or QNCX?

Do institutionals and insiders have more ownership in MTVA or QNCX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools